Full history for every metric is available with a Kvantra account
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 126 | 184 | 250 | 260 | 255 | 257 | 278 | 300 |
| Operating profit | $m | 16 | 22 | ||||||
| Net profit | $m | 17 | 18 | 26 | 11 | 1 | 7 | 11 | 22 |
| EPS reported | $ | 0.00 | 0.01 | ||||||
| Operating cashflow per share | $ | 0.02 | 0.03 | ||||||
| Capex per share | $ | 0.01 | 0.01 | ||||||
| FCF per share | $ | 0.02 | 0.02 | ||||||
| Free cash flow | $m | 32 | 37 | ||||||
| Net debt | $m | 37 | 59 | ||||||
| Book value equity | $m | 347 | 355 | ||||||
| Book value per share | $ | 0.17 | 0.17 | ||||||
| Number of shares | m | 2,027.79 | 2,033.14 | ||||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | 37.78 | - | ||||||
| P/B LTM | x | 0.75 | 0.86 | ||||||
| P/S LTM | x | 1.01 | 1.10 | ||||||
| P/FCF LTM | x | 8.07 | 8.33 | ||||||
| EV/EBITDA LTM | x | 8.39 | 6.80 | ||||||
| EV/Sales LTM | x | 1.37 | 1.31 | ||||||
| Earnings Yield LTM | % | 2.65% | 3.47% | ||||||
| FCF Yield | % | 12.39% | 12.00% | ||||||
| Quality | |||||||||
| ROE | % | 1.96% | 3.02% | ||||||
| ROIC | % | 1.90% | 2.83% | ||||||
| Operating margin | % | 6.26% | 7.89% | ||||||
| Gross margin | % | 26.96% | 25.79% | ||||||
| FCF/Sales | % | 12.57% | 13.17% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | +750.00% | +188.89% | ||||||
| Sales Growth YoY | % | +0.70% | +9.86% | ||||||
| Net Income Growth YoY | % | - | +176.53% | ||||||
| FCF Growth | % | +118.76% | -45.64% | ||||||
| Operating Profit Growth | % | +71.95% | +76.60% | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | 0.00% | 0.00% | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | 0.25 | 0.26 | ||||||
| Net Debt/EBITDA | x | 2.16 | 1.97 | ||||||
| EBIT/Net interest | x | 2.12 | 3.21 | ||||||
| Net debt/market cap | % | 14.02% | 19.40% | ||||||
| Net debt/Equity | x | 0.11 | 0.17 | ||||||
| Gross debt/equity | x | 0.37 | 0.40 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
Frontage Holdings Corporation functions as a contract research organization (CRO), delivering a broad spectrum of laboratory and associated services to the pharmaceutical, biotechnology, and agrochemical sectors, alongside performing vital bioequivalence assessments. The company's diverse service portfolio includes specialized laboratory testing, covering method development, validation, sample analysis, and central laboratory operations. They also provide Chemistry, Manufacturing, and Control (CMC) support, assisting with drug product development and analysis, as well as the provision of clinical trial materials. Furthermore, Frontage offers Drug Metabolism and Pharmacokinetics (DMPK) services, encompassing study design, execution, and data interpretation for tasks such as structural optimization in early discovery, pharmacokinetic studies in rodents, and non-GLP bioanalytical analyses. Their capabilities extend to comprehensive safety and toxicology evaluations through both in vitro and in vivo studies, as well as robust bioequivalence (BE) services from design through reporting. Additionally, the company undertakes chemistry services, including contract research and custom synthesis, and provides an array of clinical services like early-stage clinical trials, BE/BA studies, biometrics, and data management. Frontage maintains a global operational footprint, with a presence in the United States, the People's Republic of China, Europe, India, Japan, South Korea, and Australia. Established in 2018 and headquartered in Exton, Pennsylvania, Frontage Holdings Corporation is a subsidiary of Hongkong Tigermed Co., Limited.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Frontage Holdings Corporation (1521.HK)
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
Frontage Holdings Corporation functions as a contract research organization (CRO), delivering a broad spectrum of laboratory and associated services to the pharmaceutical, biotechnology, and agrochemical sectors, alongside performing vital bioequivalence assessments. The company's diverse service portfolio includes specialized laboratory testing, covering method development, validation, sample analysis, and central laboratory operations. They also provide Chemistry, Manufacturing, and Control (CMC) support, assisting with drug product development and analysis, as well as the provision of clinical trial materials. Furthermore, Frontage offers Drug Metabolism and Pharmacokinetics (DMPK) services, encompassing study design, execution, and data interpretation for tasks such as structural optimization in early discovery, pharmacokinetic studies in rodents, and non-GLP bioanalytical analyses. Their capabilities extend to comprehensive safety and toxicology evaluations through both in vitro and in vivo studies, as well as robust bioequivalence (BE) services from design through reporting. Additionally, the company undertakes chemistry services, including contract research and custom synthesis, and provides an array of clinical services like early-stage clinical trials, BE/BA studies, biometrics, and data management. Frontage maintains a global operational footprint, with a presence in the United States, the People's Republic of China, Europe, India, Japan, South Korea, and Australia. Established in 2018 and headquartered in Exton, Pennsylvania, Frontage Holdings Corporation is a subsidiary of Hongkong Tigermed Co., Limited.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free